News
A company that has Donald Trump Jr. on its board touted in a press release a new “initiative” to help pharmaceutical ...
The UK’s voluntary scheme for branded medicines pricing, access and growth (known as VPAG) makes sure that the NHS does not ...
Following a barrage of letters from President Donald Trump urging 17 large pharmaceutical companies to implement Most Favored ...
Pfizer Inc. (NYSE: PFE) delivered a stronger-than-anticipated second-quarter performance, beating analyst estimates and ...
Tánaiste Simon Harris has said the introduction of the new US tariff on EU goods provides "some degree of certainty" to businesses.
Pfizer delivered a strong Q2 earnings beat, raising FY2025 guidance and demonstrating effective cost-cutting. Learn why PFE ...
The dividend yield investors could receive from Pfizer stock has risen from about 3% in early 2022 to 7% when the market ...
Pfizer CEO Albert Bourla said his company is in “very active discussions” over Trump’s request concerning most-favoured-nation pricing, according to news website FiercePharma. Bourla said he had ...
PFIZER said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting higher-than-expected second-quarter earnings on Tuesday.
On the company’s Q2 earning call, Pfizer (PFE) noted that the company’s guidance “absorbs the impact of the currently imposed ...
From tariffs to drug pricing to the FDA, biopharma CEOs find themselves pulled into policy discussions on this year’s second quarter earnings calls.
George Tidmarsh takes over temporarily at CBER following Vinay Prasad’s abrupt departure; Replimmune trial leaders protest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results